Engineering enzymes with potential against ALS and Parkinson's disease
In an advance that could one day lead to new treatments for neurodegenerative diseases, Meredith Jackrel, an associate professor of chemistry in Arts & Sciences at Washington University in St. Louis,…
In an advance that could one day lead to new treatments for neurodegenerative diseases, Meredith Jackrel, an associate professor of chemistry in Arts
Read Full Story at Phys.org →Why This Matters
The potential to engineer enzymes as therapeutic tools for neurodegenerative diseases like ALS and Parkinson’s could redefine treatment paradigms by targeting root molecular dysfunctions rather than merely managing symptoms. This approach could accelerate drug discovery timelines by leveraging precision biology, offering hope where traditional pharmaceutical interventions have struggled to penetrate the blood-brain barrier or reverse disease progression.
Background Context
Neurodegenerative diseases remain among the most intractable challenges in medicine, with current treatments limited to slowing decline rather than halting it. The field has long grappled with the difficulty of delivering large molecules like proteins to the brain, a hurdle that enzyme engineering may now begin to overcome by designing smaller, more versatile biological tools. Meanwhile, advances in structural biology and machine learning have created a fertile environment for such innovations, though funding and regulatory pathways for enzyme-based therapies are still evolving.
What Happens Next
If preclinical successes translate to human trials, the next few years could see a surge in enzyme-based therapies entering clinical development, particularly for diseases with genetic underpinnings like familial ALS. Regulatory agencies may need to adapt fast-track pathways for biologic drugs with novel mechanisms, while researchers will likely focus on optimizing delivery methods to ensure enzymes reach affected neurons. The biggest open question is whether these engineered solutions can achieve durable efficacy without triggering immune responses or unintended off-target effects.
Bigger Picture
This work aligns with a broader shift toward precision therapeutics, where biology itself is repurposed as medicine rather than relying solely on synthetic compounds. As gene therapy and CRISPR gain traction, enzyme engineering represents another frontier where the body’s own molecular machinery is harnessed for repair. The convergence of computational biology, synthetic biology, and neurogenetics suggests this could be just the beginning of a wave of targeted interventions for conditions long considered untreatable.
